RANI News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$78.5M

Volume

586.70K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesRani Therapeutics announced a $20 million registered direct offering of Class A common stock at $1.07 per share, along with pre-funded warrants, led by a sovereign wealth fund and other healthcare-focused investors. The offering is expected to close on May 27, 2026. The company is a clinical-stage biotherapeutics firm developing oral delivery technologies for biologics.GlobeNewswire Inc. · May 26, 2026

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline PrioritizationRani Therapeutics announced the appointment of Jesper Høiland as Head of Strategy, a newly created role. Høiland, who has served as a strategic adviser since 2023, brings over 30 years of pharmaceutical leadership experience, including expertise in obesity and metabolic disease. He will be responsible for shaping corporate and pipeline strategy, prioritizing internal programs, and supporting partnering efforts. Previously, Høiland held senior positions at Ascendis Pharma, Radius Health, and Novo Nordisk.GlobeNewswire Inc. · Mar 25, 2026

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~GlobeNewswire Inc. · Jun 24, 2024

Rani Therapeutics to Participate in May Investor ConferencesSAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include:GlobeNewswire Inc. · May 14, 2024

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.GlobeNewswire Inc. · May 9, 2024

Equifax Reports Weak Sales, Joins Synovus Financial And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionU.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Thursday. Shares of Equifax Inc. (NYSE: EFX) fell sharply in today’s pre-market trading after the company reported worse-than-expected first-quarter sales results and issued adjusted guidance below estimates. Equifax posted quarterly sales of $1.389 billion, missing market estimates of $1.400 billion, according to data from Benzinga Pro. Equifax shares dipped 9.5% to $215.00 in pre-market trading. Here are some big stocks recording losses in ...Benzinga · Apr 18, 2024

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionShares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 from $4.13 a year earlier. Travelers shares dipped 8.1% to $205.03 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares shot up 256% to $2.78 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goal of reaching break-even or profitability within its current operations in 2024. Edible Garden AG Incorporated (NASDAQ: EDBL) gained 112% to $9.73 after the company reported preliminary first quarter FY24 results. Sintx Technologies, Inc. (NASDAQ: SINT) jumped 53% to $0.0350. VIA optronics AG (NYSE: VIAO) shares gained 50.4% to $0.3924 after dipping over 15% on Tuesday. AERWINS Technologies Inc. (NASDAQ: AWIN) jumped 42.2% to $4.70. The Children's Place, Inc. (NASDAQ: PLCE) climbed 35.5% to $9.64 after the company announced it entered into a new financing agreement with Mithaq Capital. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) gained 32% to $5.38 after the company announced that it submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals and confirmed that its most recent proposal to acquire Vanda remains open for Vanda and its Board of Directors to consider. EZGO Technologies Ltd. (NASDAQ: EZGO) gained 28% to $2.20. EZGO entered into a strategic cooperation framework agreement with Woteam to jointly explore the Southeast Asian Market. CXApp Inc. (NASDAQ: CXAI) shares rose 25% to $4.89 after the company announced 24% ARR growth in 2023. TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) rose 19.6% to $2.0461. WiSA Technologies, Inc. (NASDAQ:Benzinga · Apr 17, 2024

Netflix To Rally Over 15%? Here Are 10 Top Analyst Forecasts For WednesdayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays cut the price target for Prologis, Inc. (NYSE: PLD) from $153 to $141. Barclays analyst Anthony Powell maintained an Overweight rating. Prologis shares fell 1.6% to close at $125.14 on Tuesday. See how other analysts view this stock. Truist Securities slashed the price target for Berry Global Group, Inc. (NYSE: BERY) from $75 to $68. Truist Securities analyst Michael Roxland downgraded the stock from Buy to Hold. Berry Global shares fell 0.4% to close at $59.23 on Tuesday. See how other analysts view this stock. Wedbush increased Netflix, Inc. (NASDAQ: NFLX) price target from $615 to $725. Wedbush analyst Michael Pachter maintained an Outperform rating. Netflix shares rose 0.3% to close at $629.24 on Tuesday. See how other analysts view this stock. Keefe, Bruyette & Woods boosted the price target ...Benzinga · Mar 27, 2024

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) -GlobeNewswire Inc. · Mar 20, 2024

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial ResultsSAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2023 and provide a business update on Wednesday, March 20 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.GlobeNewswire Inc. · Mar 15, 2024

RANIRani Therapeutics Holdings, Inc. Class A Common Stock

RANI

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any RANI yet.

Related Tickers

Earnings

Volume

586.70K

Next Earnings

November 5th